Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcomaHideshi Sugiura, Hideo Mugishima, Masashi Ando et al.|Journal of Orthopaedic Science|2010Cited by 26